Xyngari

Xyngari is a biotechnology company focused on developing next-generation therapies for cancer and immunological diseases. The company was founded by a team of seasoned industry veterans from Celgene, Bristol Myers Squibb, and Janssen, including Rupert Vessey and Peter Lebowitz. Xyngari leverages deep expertise in drug discovery and development to target high-value biological pathways through a precision medicine lens. The firm aims to create transformative medicines that address significant unmet needs in oncology and beyond. Currently operating in an early-stage development phase, Xyngari is backed by prominent life science venture capital firms such as ARCH Venture Partners and F-Prime Capital. The company is headquartered in La Jolla, California, and continues to build its internal pipeline of innovative therapeutic candidates.